

**Anti-PRAME Reference Antibody (Eureka patent anti-PRAME)
Recombinant Antibody
Catalog # APR11017****Specification**

Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) - Product Information

Application	FC, E, FTA
Primary Accession	P78395
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) - Additional Information**Target/Specificity**
PRAME**Endotoxin**

< 0.001EU/ µg, determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) - Protein Information

Name PRAME {ECO:0000303|PubMed:9047241, ECO:0000312|HGNC:HGNC:9336}

Function

Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed: [21822215](http://www.uniprot.org/citations/21822215), PubMed: [26138980](http://www.uniprot.org/citations/26138980)). The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed: [26138980](http://www.uniprot.org/citations/26138980)). In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromatin regulation (PubMed: [21822215](http://www.uniprot.org/citations/21822215)). Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic

acid-induced cell proliferation arrest, differentiation and apoptosis (PubMed:16179254).

Cellular Location

Nucleus. Chromosome. Cytoplasm Golgi apparatus. Cell membrane. Note=Associates with chromatin; specifically enriched at transcriptionally active promoters that are also bound by nuclear transcription factor Y (composed of NFYA, NFYB and NFYC) and at enhancers (PubMed:21822215). Recruited to the Golgi apparatus in response to interferon gamma (IFNG) treatment (PubMed:23460923).

Tissue Location


Expressed in testis. Detected in samples of kidney, brain and skin.

Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) - Images



Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) is more than 95% ,determined by SEC-HPLC.